Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression
Open Access
- 30 May 2013
- journal article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 1-120
Abstract
Background: 10-Hydroxycamptothecin (10-HCPT), isolated from a Chinese tree Camptotheca acuminate, inhibits the activity of topoisomerase I and has a broad spectrum of anticancer activity in vitro and in vivo. It has been shown that HCPT is more active and less toxic than conventional camptothecins and can induce cancer cell apoptosis. However, the mechanisms of HCPT-induced apoptosis in colon cancer cells remain unclear. In this study, we investigated the effects of HCPT on apoptosis of colon cancer and underlying mechanism. Methods: Cell proliferation was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay, and apoptosis was measured using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay. Expression of genes was detected using real-time reverse transcription-polymerase chain reaction (real time-PCR) and Western blot. Tumor growth in vivo was evaluated using a nude mouse xenograft model. Results: HCPT could significantly inhibit cell proliferation and induce apoptosis in colon cancer SW1116 and Colo 205 cells in dose- and time-dependent manners. HCPT treatment activated the activities of caspase 3, 7, 8 and 9, downregulated the expression of survivin, survivinΔEx3, survivin-3B and XIAP, and upregulated expression of surviving 2B. Moreover, the combination of HCPT and 5-fluorouracial (5-FU) synergistically induced apoptosis and downregulated the expression of survivin and XIAP. Knockdown of survivin and XIAP by siRNA sensitized colon cancer to HCTP-induced apoptosis. Furthermore, HCPT treatment significantly inhibited SW1116 xenograft tumor growth. Conclusions: Our results elucidate new mechanisms of HCPT antitumor by the downregulation of survivin and XIAP expression. The combination of HCPT with 5-FU or IAP inhibitors may be a potential strategy for colon cancer treatment.Keywords
This publication has 35 references indexed in Scilit:
- Expression of survivin and its four splice variants in colorectal cancer and its clinical significancesMedical Oncology, 2013
- Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsBritish Journal of Cancer, 2011
- Hydroxycamptothecin‐loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase‐8 pathway activation and disrupt tight junctionsCancer Science, 2011
- RNA interference (RNAi) of Ufd1 protein can sensitize a hydroxycamptothecin‐resistant colon cancer cell line SW1116/HCPT to hydroxycamptothecinJournal of Digestive Diseases, 2011
- Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cellsActa Pharmacologica Sinica, 2011
- Colon Cancer: An Update and Future DirectionsGastroenterology, 2010
- Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancerAsia-Pacific Journal of Clinical Oncology, 2010
- An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapyOncogene, 2004
- CamptothecinsDrugs, 2002
- Differentiation induction of human promyelocytic leukemia cells by 10-hydioxycamptothecin, a DNA topoisomerase I inhibitorDifferentiation, 1991